{
  "bio": [
    "In 2005, Andreas Struengmann and twin brother Thomas sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.",
    "They cofounded Hexal in 1986. The company launched successful versions of the cholesterol-lowering drug simvastatin.",
    "The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.",
    "Their venture portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.",
    "In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann."
  ],
  "about": [
    "After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa.",
    "He is known to love sailing, golf and skiing."
  ]
}